Fibrocytes, ahematopoietic stem cell source of fibroblasts/myofibroblasts, were previously implicated to infiltrate into the intestinal and enhance inflammation.
Introduction
Necrotizing enterocolitis (NEC) is the most common gastrointestinal disease in infants. Its incidence has become more prevalent in recent years due to the increasing survival of lowbirth weight neonates. [1, 2] The prominent pathophysiology of NEC is characterized by persistent active gastrointestinal hemorrhagic inflammatory necrosis that affects the intestinal tracts of premature neonates. Although any segments of the gastrointestinal tract can be involved, the terminal ileum and proximal colon are the most commonly involved positions. [3, 4] Over the previous 10 years, accumulating studies have penetrated all aspects of the mechanisms mediating NEC, including gut Editor: Somchai Amornyotin.
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barrier functions, vascular dysfunction, infectious complications, and intensive proinflammatory cytokine production. [5, 6] Interestingly, the anti-inflammatory cytokine interleukin-10 (IL-10) was reported to dampen the inflammatory responses and protect against NEC. [7] Although a variety of components have been implicated, the exact cellular and molecular mechanisms involved in NEC pathogenesis are unknown.
Circulating fibrocytes are round-shaped mesenchymal cells that arise from monocyte precursors. Although these cells comprise only approximately 0.1% to 0.5% of peripherally circulating cells in normal humans, they are present in injured organs and participate in many biological processes. [8] In response to injurious and inflammatory stimuli, fibrocytes are believed to undergo tissue recruitment and activation from circulation. Fibrocytes are involved in the pathologies of inflammation and fibroblast activation, which is a key regulatory step in the inflammatory response. [9] In response to acute injury stress, fibrocytes can express a macrophage-like inflammatory gene program that encodes proinflammatory cytokines and chemokine receptors involved in antigen presentation and leukocyte trafficking. Fibrocytes can also function as antigen-presenting cells for CD8 + T cell activation by expressing main histologic complex class I and II molecules and the costimulatory proteins CD80 and CD86. [10] Clinically, fibrocytes are involved in several inflammatory and fibrotic conditions, such as inflammatory bowel disease [11] and idiopathic pulmonary fibrosis. [12] However, the role of fibrocytes in NEC pathogenesis is unknown.
The purpose of this study was to test whether fibrocytes were involved in the pathogenesis of human NEC. Therefore, we evaluated the trafficked number of fibrocytes in inflamed tissues from NEC patients. We also investigated the response of tissue fibrocytes in the intestinal mucosa following exposure to bacterial components.
Methods

Patient population and sample collection
Patients with detailed clinical data were consecutively recruited from January 2013 to July 2015 at the Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China. The study protocols for consent, data collection, and privacy protection were approved by the Institutional Review Board of the Chongqing Medical University, and written informed consent was obtained from the patients' guardians. The NEC diagnosis was based on the criteria originally proposed by Bell et al and subsequently modified by Walsh and Kliegman. [13] The criteria for enrollment included a gestational age of more than 34 weeks and stage III NEC requiring bowel surgery. The exclusion criteria were patients with the presence of an acute pulmonary bacterial infection, intestinal malformation (aproctia, intestinal atresia, or Hirschsprung disease), and severe cardiac dysfunction. In addition, to minimize severity differences in the study population, patients managed in the intensive care unit (ICU) for more than 30 days were excluded. Once the NEC case was included in the present study, detailed clinical data from the medical records, including all physicians' and nurses' notes, daily flow sheets, laboratory and radiographic reports, underlying illnesses, surgical records, and medications, were reviewed by one of the investigators. Tissue was processed for histological evaluation by light microscopy to confirm the diagnosis of NEC. Patients with NEC underwent serial blood sampling preoperatively and at 1 week after laparotomy. Resected intestine remnants and 10-mL peritoneal lavage samples were obtained during laparotomy from all cases. Control groups with comparable age to patients with NEC included patients with noninflammatory conditions intestine tissue (n = 8, intussusception) and the volunteers matched by age and sex were studied as control subjects for determination of the circulating fibrocytes and serum SDF-1/CXCL12.
Isolation of fibrocytes and treatment
The peripheral blood of patients with NEC and healthy donors were subjected to peripheral blood mononuclear cells (PBMCs) isolation using a gradient with Ficoll-Paque (Amersham Biosciences, Piscataway, NJ). The PBMCs were further undertaken positive selection for CD14+ monocytes with anti-CD14 Dynabeads (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Cells were then cultured for 48 hours in fibronectin-coated dishes (BD Biosciences, San Jose, CA) in Dulbecco's modified Eagle's medium (Life Technologies, Gaithersburg, MD) supplemented with 20% fetal bovine serum (FBS; Invitrogen). Nonadherent cells were then removed by gentle aspiration, and they were cultured for another 14 days. Some of sample was further subjected to flow cytometry (FCM) analysis to determine the fibrocytes using specific fibrocyte markers. Isolated cultured fibrocytes were treated with 10 lg/mL of lipopolysaccharide (LPS, InvivoGen, San Diego) for 12 hours.
Immunohistochemistry of surgical specimens
Details of the immunohistological staining protocols were published elsewhere. [14] Briefly, deparaffinized 4-mm thick sections were incubated with the primary SDF-1/CXCL12 (1:200; R&D Systems, Minneapolis, MN) antibody for 2 hours at room temperature, followed by incubation for 1 hour with the appropriate secondary antibody. The sections were incubated with the AB enzyme reagent for 30 minutes. The peroxidase substrate was added for stain development. The sections were dehydrated, permanently mounted with mounting medium, and observed by light microscopy.
Dual immunofluorescence
The deparaffinized sections were incubated with the anti-CD45 (mouse anti-human CD45; Santa Cruz Biotechnology, Santa Cruz, CA) and anti-collagen type I (rabbit anti-human Col I; Santa Cruz Biotechnology, Santa Cruz, CA) antibodies in the previously described blocking solution. [14] This process was followed by a second incubation for 1 hour with the donkey antimouse Alexa Fluor 488 (isotype IgG, 1:200, ab21202; Invitrogen) and donkey anti-rabbit Alexa Fluor 594 (isotype IgG; 1:200, ab21207; Invitrogen) secondary antibodies. The tissue sections were counterstained with 4',6-diamidino-2-phenylindole (DAPI; 1:1000; Sigma-Aldrich, Ann Arbor, MI) and mounted with glycerol. Negative control sections were incubated with either normal rabbit serum instead of the anticollagen type I antibody or normal mouse serum instead of the anti-CD45 antibody during all of the staining procedures, and no cross-reactivity was observed. The samples were analyzed using a Zeiss Axioplan 2 fluorescence microscope (Carl Zeiss, Inc., Thornwood, NY), equipped with FITC (green), PE (red), and DAPI (blue) filter sets. All digital images were processed and merged using the Photoshop software, version 6.0 (Adobe Systems Inc., San Jose, CA). For quantitative measurement of fibrocytes, double-stained cells were counted in a field with 
Flow cytometric analysis
Three milliliters (3 mL) of peripheral venous blood was collected in a sterile test tube and frozen at -80°C before processing for FCM and the enzyme-linked immunosorbent assay (ELISA).
Freshly isolated intestinal tissues were gently minced, passed through a 40-mm cell strainer, and centrifuged at 300g. Mononuclear cells were resuspended in RPMI 1640 medium (Invitrogen, Carlsbad, CA) and stained with the PE-conjugated surface antigen anti-CD45 and PerCP-Cy5-conjugated surface antigen anti-CXCR4 (CD45-PE, 368509; CXCR4-PerCP-Cy5.5, 306515; Biolegend, San Diego, CA) or selectively PE-conjugated anti-intercellular cell adhesion molecule-1 (ICAM1) (BD Biosciences, San Jose, CA). Then, the cells were permeabilized with a Cytofix/Cytoperm kit (BD Biosciences) for intracellular antigen detection before intracellular staining of collagen-1. Next, the cell pellet was incubated with a FITC-conjugated antihuman collagen-1 antibody (Rockland Immunochemicals, Gilbertsville, PA) or the IgG isotype control for 30 minutes. The cell suspension was analyzed with a BD FACScan flow cytometer (BD Biosciences, San Jose, CA) using the CellQuest 3.2.1f1 software. All data were analyzed with the FlowJo software (Tree Star, Inc., Ashland, OR). Baseline leukocyte counts were expressed as a percentage of the total leukocyte counts.
ELISA measurement of SDF-1/CXCL12
The concentration of SDF-1/CXCL12 in the plasma and peritoneal lavage samples was determined by ELISA using commercially available ELISAs according to the manufacturer's instructions (Quantikine; R&D Systems, Minneapolis, MN). The optical densities were determined using a microtiter plate reader (Multiscan RC Type 351; Labsystems, Helsinki, Finland) at 405 nm, with a correction wavelength set at 540 or 570 nm. The blank was subtracted from duplicate readings for each standard and sample without any knowledge of survival or other clinical data. All of the analyses and calibrations were performed at least in duplicate. The mean values were used for the statistical analysis.
Quantitative real-time PCR
PBMCs were separated from whole blood by Ficoll-Hypaque density gradient centrifugation. After isolating the PBMCs, positive selection for CD14+ monocytes was performed with anti-CD14 Dynabeads (Invitrogen) according to the manufacturer's protocol. Nonadherent cells were removed, and the CD14 + monocytes were cultured for 14 days. The cultured fibrocytes were treated with 10 mg/mL of LPS (a TLR4 agonist; InvivoGen, San Diego, CA) and IL-1b (10 ng/mL) (401-ML-025; R&D Systems) separately. At the scheduled time points, the cultured cells were subjected to RNA extraction using TRIzol (Invitrogen, Carlsbad, CA). Quantitative real-time PCR was performed using proprietary primers and probes (Taqman Gene Expression Assays; Applied Biosystems, Foster City, CA) to measure mRNA expression with the primers summarized in Table 1 (synthesized by GenePharma, Inc., Shanghai, China). glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. The relative quantification method [14] was used to determine the Ct values for the PCR products of the target genes and GAPDH. The relative quantification formula was: 2
ÀDCt Â 100%, where DCt = Ct (target gene) À Ct (GAPDH) .
Statistical analysis
Statistical comparisons were conducted with GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA) and SPSS 13.0 (SPSS Inc., Chicago, IL 
Results
Patient characteristics
The baseline features of the infants are summarized in Table 1 . Thirty-two patients met the inclusion criteria for admission, with 20 cases for PBMCs measurement and 12 cases for surgical sample collection. Serial blood sampling was performed preoperatively and at 1 week after emergency gastrointestinal surgery during routine clinic visits. Control groups with comparable ages to the NEC patients included patients who required gastrointestinal tract (e.g., intussusception) resection with noninflammatory conditions (n = 8) and normal control for PBMC collection (n = 12)There were no significant differences in the demographic features of the patients between the 2 surgical groups, including the mean age, gender distribution, and initial mean body weight. Nutritional characteristics were also similar between the 2 groups as assessed by the mean serum prealbumin and albumin concentrations. In addition, there were no significant differences in the surgical approach between the patients with NEC and intussusception ( Table 2 ). The operative magnitude was evaluated by measurement of the operative time, estimated blood loss, and total units of blood transfused within the 24-hour perioperative period. View it in a separate window
Necrotizing enterocolitis is characterized by fibrocyte infiltration
The tissue specimen sections from the NEC and noninflammatory gastrointestinal tracts were evaluated with hematoxylin and eosin staining. A prominent inflammatory infiltrate was indicated in NEC patients compared with the noninflammatory gastrointestinal tract samples (Fig. 1A) . To characterize fibrocyte infiltration in NEC, the surgical specimens were subjected to immunofluorescence with CD45 and collagen-1 (ColI) to identify fibrocytes in the intestinal mucosa. The CD45+ColI+ fibrocytes were primarily Table 1 Primer sequences used for the qRT-PCR analysis. IL-1b  GGACAAGCTGAGGAAGATGC  TCGTTATCCCATGTGTCGAA  STIM1  ACCAGCATGAAGTCCTTGAG  TGAAGATGACAGACCGGAGT  TLR4  AGAACTGCAGGTGCTGGATT  AAACTCTGGATGGGGTTTCC  IL-6  AGGAGACTTGCCTGGTGAAA  CAGGGGTGGTTATTGCATCT  ICAM1  GGC TGG AGC TGT TTG AGA AC  ACT GTG GGG TTC AAC CTC TG  TNF-a  ATGAGCACTGAAAGCATGATCC  GAGGGCTGATTAGAGAGAGGTC  GAPDH ATGGGGAAGGTGAAGGTCG GGGGTCATTGATGGCAACAATA GAPDH = glyceraldehyde-3-phosphate dehydrogenase, IL = interleukin, TLR = Toll-like receptor, TNF = tumor necrosis factor.
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Liu com found in varying numbers and locations in the mucosal layers and the submucosal layers. In the inflammatory intestines of NEC patients, CD45+ColI+ fibrocytes preferentially infiltrated into the inflammatory mucosa, whereas fibrocytes were scarcely found in the intestines without inflammation (Fig. 1B) . Next, we determined the number of fibrocytes in NEC patients. Significantly higher numbers of fibrocytes were found in the NEC patients than in the patients with noninflammatory intestinal tracts (P < .01). The CD45+ColI+ fibrocyte counts in the randomly selected areas were remarkably increased in the inflammatory lesions compared with the intestines without inflammation (P < .01) (Fig. 1C) , indicating that fibrocytes might exacerbate inflammation in NEC.
Fibrocytes are increased in the plasma and local intestinal tissues of NEC patients
We determined the overall circulating fibrocyte counts in the peripheral blood and intestinal tissues using quantitative FCM analysis. As shown in Figure 2A and B, CD45+ColI+ fibrocytes were significantly elevated in the peripheral blood and intestinal tissues of the NEC patients (n = 20) compared with the patients without intestinal inflammation (n = 8) and the age-and gendermatched healthy controls (n = 12) (P = .002). The percentage of CD45+ColI+ fibrocytes/total CD45+ cells in the peripheral blood was equivalent to the percentage in the intestinal tissue. Among the numerous microenvironmental cytokines, the CXCR4/CXCL12 chemokine axis plays a key role in the homing of fibrocytes to injured tissues. Next, we characterized circulating fibrocytes by evaluating CXCR4 and ICAM1 expression because CXCR4 facilitates fibrocyte recruitment and ICAM1 may influence leukocyte trafficking. We found that the majority of the CD45+ColI+ cells expressed CXCR4 and ICAM1 (Fig. 2B, C) . In addition, CXCR4+ fibrocytes were significantly increased in the peripheral blood and the intestinal tissues from the NEC patients compared with the patients without intestinal inflammation and the healthy controls, respectively, demonstrating their enhanced ability for recruitment to wound sites. At the same time, the Figure 2C , indicating their enhanced leukocyte trafficking ability.
SDF-1/CXCL12 concentration in NEC patients
We examined the concentration of the CXCR4 ligand SDF-1/ CXCL12 in the plasma and peritoneal lavage samples from NEC patients. As illustrated in Figure 3A , the plasma concentration of this chemokine was significantly higher in the NEC patients than in the patients (n = 20) without intestinal inflammation (n = 8) and the normal subjects (n = 12). Similarly, SDF-1/CXCL12 was detected in most of the NEC peritoneal lavage samples but was undetectable in the control peritoneal lavage samples (Fig. 3B) . Next, we examined the expression and localization of CXCL12 in intestinal sections from NEC patients in which fibrocytes were found using immunohistochemistry. As shown in Figure 3C , the immunoreactive protein was strongly expressed throughout the crypts and villi of the intestinal epithelium, whereas no or weak SDF-1/CXCL12 expression was found in the samples from patients without intestinal inflammation. In addition, increased SDF-1/CXCL12 expression was noted in the submucosa and muscularis layers, which may represent SDF-1/CXCL12 induction within the inflammatory cells in these layers.
Continuous stimulation by LPS leads to TLR4 signaling activation in fibrocytes
We investigated whether fibrocytes exerted their functions through TLR signaling because TLR4 was reported to be pivotal for NEC pathogenesis. We cultured fibrocytes from peripheral blood obtained during emergency gastrointestinal surgery from NEC patients (n = 12) and patients without intestinal inflammation (n = 8) for 14 days as described in the " Methods." As shown in Figure 4A , circulating fibrocytes from NEC expressed TLR4, and this expression was elevated by LPS exposure. The important TLR4 signaling downstream molecule (release of phosphorylated p38) was also elevated upon LPS treatment (Fig. 4B) . In response to IL-1b, TNF-a mRNA expression was remarkably upregulated, which represented a proinflammatory ability in fibrocytes from NEC patients. In addition, the ICAM1 mRNA was remarkably upregulated, which would promote leukocyte trafficking. Conversely, LPS treatment significantly downregulated ColI mRNA expression (Fig. 4C) .
Discussion
This study showed a significant increase in fibrocytes (CD45 +ColI+) in the intestinal mucosa of NEC patients. Similar differences were detected for other circulating fibrocyte subpopulations, including CD45+ColI+CDCR4+ cells and CD45 www.md-journal.com +ColI+ICAM1+ cells. Furthermore, the plasma and peritoneal fluid SDF-1/CXCL12 levels were elevated in NEC patients, implying the recruitment capability of these extraintestinal cells.
We also quantified elevated levels of the pro-inflammation cytokines IL-6 and TNF-b and recruiting leukocytes in the NEC patients, suggesting their involvement in the pathogenesis of this disease. Cultured fibrocytes from the patients activated inflammatory TLR4 signals in response to LPS, suggesting that these cells may contribute to the accelerated inflammation by producing several proinflammatory cytokines. Fibrocytes were revealed to be effector cells in chronic inflammation and were implicated in the pathogenesis of the chronic inflammatory state. [15, 16] Consistent with this finding, we demonstrated for the first time a significant increase of fibrocytes in the intestine in NEC patients compared with resected intestines from patients with noninflammatory gastrointestinal conditions. This increase was consistently noted in all 12 NEC specimens with a variable spectrum of intestinal injury, although we could not correlate the abundance of fibrocytes with the severity of the intestinal injury. The results of the present study were in line with studies showing that fibrocytes emerged in inflammatory tissues, including colitis, asthma, Crohn disease, scleroderma, Graves' disease, and rheumatoid arthritis. [17] [18] [19] [20] To the best of our knowledge, no other studies have demonstrated the presence of fibrocytes in NEC patients. Our previous data demonstrated that the appearance of spindle-shaped mature fibrocytes and a-SMA myofibroblasts occurred during the healing phase of bronchopulmonary dysplasia, suggesting that these cells were recruited to repair the damage and not simply to amplify inflammation. Another possibility is that fibrocytes in the inflamed intestine may have a protective mechanism as suggested in other diseases, such as idiopathic pulmonary fibrosis. Another study showed that the number of fibrocytes was decreased in the fibrotic tissues of patients with Crohn disease, [18, 21] which seemed to be paradoxical according to the hypothesis that fibrocytes were directly involved in the inflammatory reaction of NEC. Although it is beyond the scope of this study to speculate that fibrocytes may play a role in the repair of the mucosa, the induction of fibrocytes suggests a role in the inflammatory response of NEC. The comprehensive function of fibrocytes in NEC pathogenesis should be investigated in long-term processes in a future study.
The chemokine receptors CXCR4 and CCR7 are reported to be pivotal for the recruitment of fibrocytes to injured sites. [22, 23] Here, we confirmed that a major proportion of human fibrocytes (nearly 80%) in the peripheral blood of NEC patients expressed CXCR4. At the same time, the CXCR4 receptors were present at a high level in the serum samples from NEC patients, which was similar to observations in patients with fibrotic lung disease. [24, 25] Moreover, neutralization of CXCL12 using antibodies resulted in reduced recruitment of circulating fibrocytes to the injured lung and attenuated fibrosis. [26] The presence of these chemokine receptors further implied that the fibrocytes of patients isolated with CD45 and Col-I from peripheral blood leukocytes had a high ability to infiltrate to the injured sites, although no similar blocking experiment was performed to investigate their mechanism in gastroenterological disease. Some studies have proposed that fibrocytes are putative effector cells in the progression of inflammation in Crohn disease, where the accumulation of fibrocytes was found in the inflamed intestinal mucosa. Our results revealed that tissues fibrocytes were preferentially found in areas of inflammation close to inflammatory cells, such as Medicine macrophages and T lymphocytes, which potentially represents a process of migration and homing of these cells to these intestinal cell populations. During inflammation episodes, ICAM1 is primarily responsible for the migration and recruitment of neutrophils, monocytes, and macrophages into tissues in response to injury. [27] Importantly, we showed a significantly higher population of ICAM1-positive circulating fibrocytes in NEC patients than the controls, suggesting a high ability for leukocyte trafficking in NEC pathogenesis.
At present, it is unclear by which molecular mechanisms fibrocytes amplify the inflammatory and immune responses. The TLR ligand LPS is regarded as a predominant signal transduction pathway involved in exacerbating a wide variety of inflammatory genes in the intestinal mucosa during NEC pathogenesis. [28, 29] We specifically examined TLR4 activation in isolated fibrocytes by LPS treatment and demonstrated for the first time that cultured human fibrocytes derived from the peripheral blood of patients with NEC expressed the TLR4 mRNA. In addition, we demonstrated that various cytokines (e.g., inflammatory cytokines, such as TNF-a and IL-6, and tissue remodeling factors, such as ColI) were increased in infants with NEC and might be responsible for the induction of TLR4 activation in NEC. Recent studies have shown that fibrocytes stimulated by TLR ligands produce a higher amount of IL-6 than the plasmacytoid dendritic cells. [30] LPS treatment specifically and remarkably upregulated the TNF-a and ColI mRNA levels in fibrocytes. Consistent with this finding, our investigation of signaling pathways in fibrocytes suggested that TLR signaling affected the function of the fibrocytes, thereby supporting the hypothesis that fibrocytes could infiltrate into the bacterial component rich environment and respond to TLR ligands in the inflammatory intestinal tissue of NEC patients. We postulate that fibrocytes may potentially be an even more attractive target for the treatment of inflammatory intestinal conditions because they are the sources of IL-6 and other proinflammatory cytokines.
Certain weakness should be considered in this study. Due to the purely cross-sectional design of the present study and the small sample size, we did not draw a line between the circulating fibrocytes infiltrated into the inflammatory lesions and NEC, although these cells were present in the intestinal mucosa of the NEC patients. Although these questions remain open, the current study has described circulating fibrocytes as a unique inflammatory infiltration profile observed in NEC, which supports the proinflammatory role of circulating fibrocytes involved in NEC pathogenesis. Further elucidation of the nature and the contribution of fibrocyte infiltration will be essential. 
Conclusion
For the first time, we found increased fibrocyte counts in NEC patients that were possibly involved in the pathogenesis of this disease. The fibrocytes might enhance inflammation by TLR4 signaling to promote cytokine activation and leukocyte recruitment. However, these findings should be confirmed or refuted by larger studies. To understand the contribution of fibrocytes and to identify a potential therapeutic target for the effective treatment of this disorder, complementary studies should investigate the additive effects of fibrocytes in detail.
